Summit Therapeutics (SMMT) Retained Earnings (2018 - 2026)
Summit Therapeutics' (SMMT) quarterly Retained Earnings came in at $3.3 billion in Q2 2026, up 58.44% YoY from $2.1 billion in Q2 2025, and up 9.91% on a QoQ basis from $3.0 billion in Q1 2026.
Summit Therapeutics (SMMT) Retained Earnings (2018 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 9 years of Retained Earnings data on file, last reported at $3.3 billion in Q2 2026.
- Quarterly Retained Earnings rose 58.44% year-over-year to $3.3 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $3.3 billion (up 58.44% YoY) and the FY2025 annual result came in at $2.9 billion, up 84.44% from the prior year.
- Retained Earnings improved to $3.3 billion in Q2 2026, from $3.0 billion in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $3.3 billion in Q2 2026 to a low of $388.3 million in Q1 2022.
- A 5-year average of $1.5 billion and a median of $1.2 billion in 2024 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2023 — Retained Earnings jumped 170.03% — and 2024, when it grew 2.65%.
- Tracing SMMT's Retained Earnings over 5 years: stood at $504.8 million in 2022, then surged by 111.26% to $1.1 billion in 2023, then jumped by 49.87% to $1.6 billion in 2024, then jumped by 84.44% to $2.9 billion in 2025, then grew by 12.76% to $3.3 billion in 2026.
- The last three Retained Earnings figures came in at $3.3 billion (Q2 2026), $3.0 billion (Q1 2026), and $2.9 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | 3.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.32 Bn |
| Mar 31, 2026 | 3.02 Bn |
| Dec 31, 2025 | 2.95 Bn |
| Sep 30, 2025 | 2.26 Bn |
| Jun 30, 2025 | 2.10 Bn |
| Mar 31, 2025 | 1.62 Bn |
| Dec 31, 2024 | 1.60 Bn |
| Sep 30, 2024 | 1.59 Bn |
| Jun 30, 2024 | 1.29 Bn |
| Mar 31, 2024 | 1.08 Bn |
| Dec 31, 2023 | 1.07 Bn |
| Sep 30, 2023 | 1.05 Bn |
| Jun 30, 2023 | 1.05 Bn |
| Mar 31, 2023 | 1.05 Bn |
| Dec 31, 2022 | 504.77 Mn |
| Sep 30, 2022 | 493.55 Mn |
| Jun 30, 2022 | 391.22 Mn |
| Mar 31, 2022 | 388.33 Mn |
| Dec 31, 2021 | 384.05 Mn |
| Sep 30, 2021 | 377.21 Mn |